UHUwe Hillen

Uwe Hillen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uwe Hillen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mutations in γ-secretase subunit–encoding PSENEN underlie Dowling-Degos disease associated with acne inversa

    by Damian J. Ralser, F. Buket Ü. Basmanav, Aylar Tafazzoli, Jade Wititsuwannakul, Sarah Delker, Sumita Danda, Holger Thiele, Sabrina Wolf, Michélle Busch, Susanne A. Pulimood, et al.

    Dowling-Degos disease (DDD) is an autosomal-dominant disorder of skin pigmentation associated with mutations in keratin 5 (KRT5), protein O-fucosyltransferase 1 (POFUT1), or protein O-glucosyltransferase 1 (POGLUT1). Here, we have identified 6 heterozygous truncating mutations in PSENEN, encoding presenilin enhancer protein 2, in 6 unrelated patients and families with DDD in whom mutations in KRT5, POFUT1, and POGLUT1 have been excluded. Further examination revealed that the histopathologic feature of follicular hyperkeratosis distinguished these 6 patients from previously studied individuals with DDD. Knockdown of psenen in zebrafish larvae resulted in a phenotype with scattered pigmentation that mimicked human DDD. In the developing zebrafish larvae, in vivo monitoring of pigment cells suggested that disturbances in melanocyte migration and differentiation underlie the DDD pathogenesis associated with PSENEN. Six of the PSENEN mutation carriers presented with comorbid acne inversa (AI), an inflammatory hair follicle disorder, and had a history of nicotine abuse and/or obesity, which are known trigger factors for AI. Previously, PSENEN mutations were identified in familial AI, and comanifestation of DDD and AI has been reported for decades. The present work suggests that PSENEN mutations can indeed cause a comanifestation of DDD and AI that is likely triggered by predisposing factors for AI. Thus, the present report describes a DDD subphenotype in PSENEN mutation carriers that is associated with increased susceptibility to AI.


  • Ulcera crurum bei Fremdkörperreaktion nach Silikoninjektion

    by Ioana Cosgarea, Annemarie Gutzeit, Uwe Hillen, Joachim Dissemond

  • Open Access

    Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection

    by Wiebke Sondermann, Klaus G. Griewank, Bastian Schilling, Elisabeth Livingstone, Julia C. Leyh, Natalia Rompoti, Ioana Cosgarea, Tobias Schimming, Dirk Schadendorf, Lisa Zimmer, et al.

    We have previously demonstrated an impact of the BRAF inhibitor vemurafenib on patient lymphocyte counts. In the current study, the extent to which concomitant use of corticosteroids in BRAF inhibitor treated patients affects lymphocyte counts and predisposes to infection was investigated. A cohort of 102 patients receiving either the selective BRAF inhibitor vemurafenib or dabrafenib was analyzed. The amount of patients receiving either medication with or without systemic corticosteroids (dexamethasone) was determined and lymphocyte counts before and under therapy assessed. Additionally, the number and severity of infections occurring in these groups was analyzed. Vemurafenib treatment led to a considerable decrease in lymphocyte cell counts, with 62.3% of patients having lymphopenia. Dabrafenib treated patients only rarely demonstrated lymphopenia (12.5%). Dexamethasone co-administration further diminished lymphocyte counts. Lymphopenias were observed in 84.6% of patients receiving vemurafenib and dexamethasone. In our cohort, infections were noted in 9 patients, 4 of these were severe and 2 eventually fatal. All 9 cases with infections demonstrated lymphopenia, 8 of these had received dexamethasone and 7 of these a therapy with vemurafenib. Our findings demonstrate a significant lymphopenia in patients treated with the BRAF inhibitor vemurafenib, which is further augmented by dexamethasone and predisposes to infection. If validated in other studies, risk of infection should be considered when applying corticosteroids in combination with BRAF inhibitors, in particular vemurafenib.


  • Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly woman

    by E. Livingstone, U. Hillen, C. Hafner, S. Piel, L. Groesser, D. Schadendorf, R. Happle

    Epidermal naevi (EN) are considered mosaic disorders. Postzygotic mutations are thought to occur during early embryogenesis. They are usually arranged along Blaschko's lines and tend to be noted either at birth or shortly thereafter. Skin tumours arising on EN are occasionally reported, with ongoing discussion as to whether these are collision tumours or a malignant transformation of the EN. We describe a 76‐year‐old woman with segmentally arranged seborrhoeic keratoses that showed impending atypia and, in one lesion, even overt malignant transformation. In biopsies from various lesions we found FGFR3 and PIK3CA hotspot mutations but there was no consistent pattern of mutations explaining the premalignant or malignant growth. So far it is unclear whether the precancerous changes as noted in this elderly patient can be taken as an unusual manifestation of one of the established types of EN, or whether this may represent a separate disorder that could be called ‘SASKIA naevus’. The acronym would stand for segmentally arranged seborrhoeic keratoses with impending atypia.


  • Vesikel und Pusteln auf schmerzhaften erythematösen Plaques

    by Ioana Cosgarea, Uwe Hillen, Joachim Dissemond

  • Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft‐versus‐host disease

    by U. Hillen, P. Häusermann, D. Massi, A. Janin, D. Wolff, A. Lawitschka, H. Greinix, R. Meyer, M. Ziemer

    Background: Histopathological diagnosis including selection of lesions, the determination of the best point of time for biopsy and workup is not trivial in cutaneous graft‐versus‐host disease (GvHD).Objectives: To develop interdisciplinary recommendations on performing, the laboratory work up and reporting of the results of skin biopsies in patients with suspected cutaneous GvHD.Methods: A working group consisting of dermatopathologists, dermatologists, transplant‐physicians and transplant‐pathologists prepared recommendations for performing skin biopsies, laboratory workup and evaluation of tissue samples, and reporting of the results in patients with cutaneous GvHD. After achieving a consensus within the working group, a survey that comprised the core issues of the recommendations was electronically sent out to 72 alloHSCT centres within Germany, Austria, and Switzerland and their Departments of Pathology. The answers were discussed in a Consensus Conference and final recommendations were established.Results: Twenty‐five centres responded to the clinical and 17 centres to the histopathological survey. Questions addressed to the clinicians comprised the indication for skin biopsy in chronic GvHD (cGvHD) and acute GvHD (aGvHD) and the appropriate point of time for skin biopsy. Eighty‐eight per cent agreed that the skin biopsy is generally indicated in patients with suspected cGvHD lacking diagnostic features. In contrast, with suspected aGvHD, only 62% of respondents felt that skin biopsy was necessary even if GvHD had not been confirmed in another organ. Although restricted due to the fact that immunosuppression is often applied in an emergency setting most centres supported skin biopsies before initiation of topical or systemic immunosuppression. The majority of pathologists agreed that in non‐sclerotic GvHD a punch biopsy is adequate, whereas in sclerotic GvHD a scalpel biopsy is preferred.Conclusion: While a consensus on the need for biopsies in cGvHD was reached the value of skin biopsies in aGvHD and subsequent biopsies during therapy requires further evaluation.


  • Dermatoonkologie

    by C. Ulrich, U. Hillen, R. Gutzmer


  • Kutanes Plattenepithelkarzinom unter Berücksichtigung besonderer Patientengruppen

    by U. Hillen, M. Ulrich, M. Alter, J.C. Becker, R. Gutzmer, U. Leiter, A. Lonsdorf, A. Messerschmidt, C. Ulrich

    Die malignen epithelialen Tumore haben eine steigende Inzidenz. Das kutane Plattenepithelkarzinom (PEK) ist ein Tumor des höheren Lebensalters. Aufgrund der steigenden Lebenserwartung ist mit einer zunehmenden Häufigkeit der Erkrankung zu rechnen. In der Regel hat das PEK eine gute Prognose. Die Therapie besteht in der mikroskopisch kontrollierten Chirurgie des Tumors. Fortgeschrittene und metastasierte PEK stellen dagegen eine therapeutische Herausforderung dar. Bei Patienten mit Lymphknotenmetastasen liegen die 10-Jahres-Überlebensraten unter 20 %, bei Patienten mit Fernmetastasen unter 10 %. Immunsupprimierte haben ein erhöhtes Metastasierungsrisiko. Der Beitrag gibt eine Übersicht über das PEK unter besonderer Berücksichtigung der Patientengruppen, die einem erhöhten Risiko ausgesetzt sind. The incidence of non-melanoma skin cancer (NMSC) is increasing. Squamous cell carcinoma of the skin (SCC) is a tumor of the elderly. Due to the increasing life expectancy, SCC will become more and more frequent in the future. Generally SCC has a favorable prognosis. Standard therapy is microscopically- controlled excision. Therapy of advanced and metastatic SCC is still challenging. Patients with regional lymph node metastasis have ten-year survival rates less than 20 %; patients with distant metastases less than 10 %. Immunosuppression has been shown to be one of the key prognostic factors for metastasis. The article reviews SCC and focusses on patients being at risk for an unfavorable course.


  • Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

    by Uwe Hillen, Claas Ulrich, Ralf Gutzmer, Jürgen C Becker

  • Open Access

    Lack of SF3B1 R625 mutations in cutaneous melanoma

    by Bastian Schilling, Nicola Bielefeld, Antje Sucker, Uwe Hillen, Lisa Zimmer, Dirk Schadendorf, Michael Zeschnigk, Klaus G Griewank

    Melanoma is a deadly disease affecting people worldwide. Genetic studies have identified different melanoma subtypes characterized by specific recurrently mutated genes and led to the successful clinical introduction of targeted therapies. Hotspot mutations in SF3B1 were recently reported in uveal melanoma. Our aim was to see if these mutations also occur in cutaneous melanoma.